Lates News

According to AI Express News, Open Source Securities released a research report on May 20th, giving a buy rating to Yiping Hong (300723.SZ). The main reasons for the rating include: 1) The rapid progress of the gout new drug AR882, with great potential in domestic and foreign markets; 2) Continuous increase in research and development investment, with frequent highlights in the early research pipeline. (Daily Economic News)